Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Ascendis Pharma A/SNASDAQ: ASND

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit grows, but more slowly than its trailing trend

Q3 FY2026 gross profit of €335.16M rose 75.2% year over year, behind the +95.1% change in trailing-twelve-month gross profit. Sequentially, it rose 7.2% from the prior quarter. Over 3 fiscal years it compounded at +147.0% a year.

Context

  • Gross profit amounted to 85.1% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +75.2% toward the trailing-twelve-month pace of +95.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
€335.16M+7.2% QoQ
Last fiscal yearDec 2025
€588.53M+84.3% YoY
LTMSep 2026
€1.09B+95.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+75.2%——
1 year+84.3%——
3-year CAGR+147.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
588.53M EUR
Year-over-year change
+84.3%
4-year CAGR
+242.9%

Gross Profit vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +95.1% is the 4th highest of 11, against a peer median of +26.6%.
  • Gross profit amounts to 90.6% of revenue for ASND, versus a peer median of 83.6%.
ASND Competitors
Gross Profit for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$821.17B USD+32536.1%+16.0%79.9%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$3.62B USD+37.2%+24.2%97.8%
UTHRUnited Therapeutics CorporationLTM Jun 2026$2.72B USD-0.8%+16.1%86.1%
ASNDAscendis Pharma A/SLTM Sep 2026€1.09B EUR+95.1%+147.0%90.6%
INSMInsmed IncorporatedLTM Jun 2026$947.34M USD+214.3%+36.3%83.3%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$816.73M USD+15.9%+23.6%98.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$559.44M USD+11.3%+19.0%83.6%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$256.89M USD+42.5%+39.6%81.6%
SEPNSepterna, Inc.LTM Sep 2026$76.97M USD+249.1%—79.9%
STOKStoke Therapeutics, Inc.LTM Mar 2026$28.99M USD-84.7%+145.9%90.4%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$124K USD-24.0%——
Peer median (excluding ASND) —+26.6%+23.9%83.6%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.